BidaskClub lowered shares of Iradimed (NASDAQ:IRMD) from a sell rating to a strong sell rating in a research report report published on Thursday morning, BidAskClub reports.

Several other equities research analysts have also recently commented on IRMD. Zacks Investment Research raised Iradimed from a hold rating to a buy rating and set a $26.00 price target for the company in a research note on Saturday, October 26th. ValuEngine raised Iradimed from a hold rating to a buy rating in a research note on Thursday, February 6th.

NASDAQ:IRMD traded up $0.67 on Thursday, hitting $26.64. 58,434 shares of the company’s stock traded hands, compared to its average volume of 52,408. The company has a current ratio of 9.82, a quick ratio of 9.05 and a debt-to-equity ratio of 0.05. Iradimed has a 1 year low of $16.68 and a 1 year high of $29.80. The firm has a 50-day moving average price of $25.43 and a 200-day moving average price of $23.10. The company has a market cap of $294.23 million, a PE ratio of 34.15 and a beta of 1.65.

Iradimed (NASDAQ:IRMD) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $0.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.10. Iradimed had a return on equity of 18.95% and a net margin of 25.01%. The company had revenue of $10.89 million for the quarter, compared to analysts’ expectations of $10.96 million. On average, research analysts forecast that Iradimed will post 0.77 EPS for the current fiscal year.

In related news, Director Anthony Vuoto sold 5,288 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $23.40, for a total value of $123,739.20. Following the completion of the sale, the director now owns 15,029 shares of the company’s stock, valued at approximately $351,678.60. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Brent Johnson sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $22.86, for a total value of $137,160.00. Following the completion of the sale, the vice president now directly owns 7,368 shares of the company’s stock, valued at approximately $168,432.48. The disclosure for this sale can be found here. In the last three months, insiders sold 140,695 shares of company stock valued at $3,331,610. 56.80% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC boosted its position in Iradimed by 109.3% during the third quarter. Tower Research Capital LLC TRC now owns 2,024 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 1,057 shares during the period. Victory Capital Management Inc. boosted its position in Iradimed by 36.6% during the fourth quarter. Victory Capital Management Inc. now owns 4,731 shares of the medical equipment provider’s stock worth $111,000 after purchasing an additional 1,268 shares during the period. Barclays PLC boosted its position in Iradimed by 88.3% during the third quarter. Barclays PLC now owns 5,352 shares of the medical equipment provider’s stock worth $113,000 after purchasing an additional 2,509 shares during the period. UBS Group AG boosted its position in Iradimed by 29.4% during the fourth quarter. UBS Group AG now owns 6,284 shares of the medical equipment provider’s stock worth $147,000 after purchasing an additional 1,427 shares during the period. Finally, Marshall Wace LLP bought a new stake in Iradimed during the first quarter worth approximately $241,000. 25.82% of the stock is owned by hedge funds and other institutional investors.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Read More: What is a stock buyback?

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.